Prasugrel Safety Profile & Adverse Events

Safety Profile Overview

Irreversible P2Y12 inhibitor for ACS patients undergoing PCI. More potent antiplatelet effect but higher bleeding risk versus clopidogrel.

Generic Name

prasugrel

Brand Names

Effient

Therapeutic Class

P2Y12 Inhibitor

Manufacturer

Eli Lilly

What Pharma Signal Tracks for Prasugrel

Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Prasugrel, including serious outcomes, hospitalizations, and deaths.
FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Prasugrel products.
Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Prasugrel Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Prasugrel.

curl "https://api.pharma-signal.com/drug/safety/prasugrel" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Try the API API Reference

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Prasugrel against other P2Y12 Inhibitor drugs, or explore the full manufacturer portfolio for Eli Lilly.

Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
Therapeutic class benchmarking — See how Prasugrel ranks within P2Y12 Inhibitor on serious event rates.
Company portfolio risk — View all drugs from Eli Lilly with aggregate risk exposure.
AI analyst briefs — Get a natural-language safety assessment combining all data sources.